Frequency of adverse drug reactions in hospitalized patients: A systematic review and meta-analysis

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 11, 2012, Pages 1139-1154

  Miguel, Ana ^a   Azevedo, Luís Filipe ^a   Araújo, Manuela ^a   Pereira, Altamiro Costa ^a  

^a University of Porto   (Portugal)

Author keywords

Adverse drug reactions; Hospital; Incidence; Meta analysis; Pharmacoepidemiology; Systematic review

Indexed keywords

ADVERSE DRUG REACTION; COCHRANE LIBRARY; DATA BASE; DRUG SURVEILLANCE PROGRAM; EMBASE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; POPULATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; WORLD HEALTH ORGANIZATION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DATABASES, BIBLIOGRAPHIC; DRUG TOXICITY; HOSPITALIZATION; HUMANS; INCIDENCE; INPATIENTS; PHARMACEUTICAL PREPARATIONS; PROSPECTIVE STUDIES; RISK;

EID: 84868207501     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3309     Document Type: Review

References (56)

1. D'Arcy PF, Griffin JP. Thalidomide revisited. Adverse Drug React Toxicol Rev 1994; 13: 65-76.
2. Routledge P. 150 years of pharmacovigilance. Lancet 1998; 351: 1200-1201.
3. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279(15): 1200-1205.
4. Kvasz M, Allen IE, Gordon MJ, et al. Adverse drug reactions in hospitalised patients: A critique of a meta-analysis. Medsc Gen Med 2000; 2: E3.
5. Kongkaew C, Noyce PR, Ashcroft DM. Hospital Admissions Associated with Adverse Drug Reactions: A Systematic Review of Prospective Observational Studies. Ann Pharmacother 2008; 42: 1-9.
6. Dartnell JGA, Anderson RP, Chohan V, et al. Hospitalisation for adverse events related to drug therapy: incidence, avoidability and costs. Med J Aust 1996; 164: 659-662.
7. Kjustad L, Klemetsdal B, Pape J. Adverse effects of drugs in the elderly: reasons for hospitalization. Tidsskr Nor Laegeforen 1987; 107: 551-552.
8. Classen DC, Pestonik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients: excess length of stay, extra costs and attributable mortality. JAMA 1997; 277: 301-306.
9. Johnson JA, Bootman JL. Drug-related morbidity and mortality. Arch Intern Med 1996; 155: 1949-1956.
10. Bates DW, et al. The costs of adverse drug events in hospitalized patients. JAMA 1997; 277: 307-311.
11. Pirmohamed M, Park BK. Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci 2001; 22(6): 298-305.
12. Davies EC, Green CF, Mottram DR, Pirmohamed M. Adverse drug reactions in hospitals: a narrative review. Curr Drug Saf 2007; 2: 79-87.
13. Palaian S, Mishra P, Shankar PR, Dubey AK, Bista D, Almeida. Safety monitoring of drugs - Where do we stand? Kathmandu Univ Med J 2006; 4; 1(13): 119-127.
14. Lee A, Thomas SHL. Adverse drug reactions. In Clinical Pharmacy and Therapeutics (3rd edn), Walker R, Edwards C (eds). Churchill Livingstone publishers: Philadelphia, 2002; 33-45.
15. Cuervo LG, Clarke M. Balancing benefits and harms in health care. Br Med J 2003; 327(7406): 65-66.
16. Loke YK, Price D, Herxheimer A. Systematic reviews of adverse effects: framework for a structured approach. BMC Med Res Methodol 2007; 7: 32.
17. Cornelius VR, Perrio MJ, Shakir SAW, Smith LA. Systematic reviews of adverse effects of drug interventions: a survey of their conduct and reporting quality. Pharmacoepidemiol Drug Saf 2009; 18: 1223-1231.
18. McIntosh HM, Woolacott NF, Bagnall AM. Assessing harmful effects in systematic reviews. BMC Med Res Methodol 2004; 4: 19.
19. Chou R, Fu R, Carson S, Saha S, Helfand M. Methodological shortcomings predicted lower harm estimates in one of two sets of studies of clinical interventions. J Clin Epidemiol 2007; 60(1): 18-28.
20. Howard RL, Avery AJ, Slavenburg S, et al. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol 2006; 63(2): 136-147.
21. Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. In Textbook of Adverse Drug Reactions, Davies DM (ed.). Oxford University press: Oxford, 1977.
22. World Health Organization. International Drug Monitoring: The Role of the Hospital. Geneva, Switzerland: World Health Organization; 1966. Technical Report Series No. 425.
23. Karch FE, Lasagna L. Adverse drug reaction- a critical review. JAMA 1975; 234: 1236-1241.
24. Edwards IR, Aronson JK. ADRs: definition, diagnosis and management. Lancet 2000. 356: 1255-1259.
25. Nebeker JR, Barach P, Samore MH. Clarifying Adverse Drug Events: A Clinician's Guide to Terminology, Documentation, and Reporting. Ann Intern Med 2004; 140: 795-801.
26. The Cochrane Collaboration. Cochrane Handbook for systematic reviews of interventions version 5.0.0. 2008; 434-449.
27. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 2009; 6(6): e1000097. DOI: 10.1371/journal.pmed1000097
28. Sweetman S (Ed). Martindale: The Complete Drug Reference. Pharmaceutical Press: London. Electronic version. Ed 36, 2009; 239-326.
29. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245.
30. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992; 49: 2229-2232.
31. Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm 1992; 27: 538.
32. Vandenbroucke JP, von Elma EE, Altman DG, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. PLoS Med 2007; 4(10): e297.
33. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 1999; 354(9193): 1896-1900.
34. Bates DW, Leape LL, Petrycki S. Incidence and Preventability of Adverse Drug Events in Hospitalized Adults. J Gen Intern Med 1993; 8: 289-294.
35. Moore N, Leocointre D, Noblet C, Mabille M. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol 1998; 45: 301-308.
36. Gholami K, Shalviri G. Factors associated with preventability, predictability, and severity of adverse drug reactions. Ann Pharmacother 1999; 33: 236-240.
37. Martinez-Mir I, Lopez MG, Palop V, Ferrer JM, Rubio E, Morales-Olivas FJ. A prospective study of adverse drug reactions in hospitalized children. Br J Clin Pharmacol 1999; 47: 681-688.
38. Van den Bemt PMLA, Egberts ACG, Lenderink AW, et al. Risk factors for the development of adverse drug events in hospitalized patients. Pharm World Sci 2000; 22(2): 62-66.
39. Fattinger K, Roos M, Veregeres P, et al. Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine. Br J Clin Pharmacol 2000; 49: 158-167.
40. Buajordet I, Ebbesen J, Erikssen J, Brérs O, Hilberg T. Fatal adverse drug events: the paradox of drug treatment. J Intern Med 2001; 250: 327-341.
41. Weiss J, Krebs S, Hoffmann C, et al. Survey of Adverse Drug Reactions on a Pediatric Ward: A Strategy for Early and Detailed Detection. Pediatrics 2002; 110: 254-257.
42. Egger T, Dormann H, Ahne G, et al. Identification of Adverse Drug Reactions in Geriatric Inpatients Using a Computerised Drug Database. Drugs Aging 2003; 20(10): 769-776.
43. Ramesh M, Pandit J, Parthasarathi G. Adverse drug reactions in a South Indian hospital-their severity and cost involved. Pharmacoepidemiol Drug Saf 2003; 12: 687-692.
44. Somers A, Petrovic M, Robays H, Bogaert M. Reporting adverse drug reactions on a geriatric ward: a pilot project. Eur J Clin Pharmacol 2003; 58: 707-714.
45. Vargas E, Terleira A, Hernando F, et al. Effect of adverse drug reactions on length of stay in surgical intensive care units. Crit Care Med 2003; 31(3): 694-698.
46. Fattahi F, Pourpak Z, Moin M, et al. Adverse drug reactions in hospitalised children in a department of infectious diseases. J Clin Pharmacol 2005; 45: 1313-1318.
47. Haffner S, von Laue N, Wirth S, Thurmann PA. Detecting Adverse Drug Reactions on Paediatric Wards Intensified Surveillance Versus Computerised Screening of Laboratory Values. Drug Saf 2005; 28(5): 453-464.
48. Camargo AL, Ferreira MBC, Heineck I. Adverse drug reactions: a cohort study in internal medicine units at a university hospital. Eur J Clin Pharmacol 2006; 62: 143-149.
49. Santos DB, Coelho HL. Adverse drug reactions in hospitalized children in Fortaleza, Brazil. Pharmacoepidemiol Drug Saf 2006; 15: 635-640.
50. Tribiño G, Maldonado C, Segura O, Díaz J. Costos directos y aspectos clínicos de las reacciones adversas a medicamentos en pacientes hospitalizados en el servicio de medicina interna de una institución de tercer nivel de Bogotá. Biomedica 2006; 26: 31-41.
51. Arulmani R, Rajendran SD, Suresh B. Adverse drug reaction monitoring in a secondary care hospital in South India. Br J Clin Pharmacol 2006; 65(2): 210-216.
52. Zopf Y, Rabe C, Neubert A, Hahn EG, Dormann H. Risk Factors Associated with Adverse Drug Reactions Following Hospital Admission A Prospective Analysis of 907 Patients in Two German University Hospitals. Drug Saf 2008; 31(9): 789-798.
53. Joshua L, Devi P, Guido S. Adverse drug reactions in medical intensive care unit of a tertiary care hospital. Pharmacoepidemiol Drug Saf 2009; 18: 639-645.
54. Pourseyed S, Fattahi S, Pourpak Z, et al. Adverse drug reactions in patients in an Iranian department of internal medicine. Pharmacoepidemiol Drug Saf 2009; 18: 104-110.
55. Santos L, Martinbiancho JK, Silva MM, Silva RG. Reações adversas a medicamentos em unidades pediátricas gerais de um Hospital Universitário. Lat Am J Pharm 2009; 28(5): 695-699.
56. Beijer HJM, de Blaey CJ. Hospitalisations caused by adverse drug reactions: a meta-analysis of observational studies. Pharm World Sci 2002; 24: 46-54.